Redefining clinical trials: Adopting AI for speed, volume and diversity
IBM Big Data Hub
MAY 6, 2024
Our analysis of the voluntarily reported Form FDA 1572 BMIS database reveals a potential lack of sustainability in the investigator pool, both in the United States (US) and globally (Exhibit 2). IBM is at the forefront of adopting AI for the pharmaceutical business, showcasing our commitment to refining this domain.
Let's personalize your content